Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment.

Abstract excerpt

Antiangiogenic treatments have shown activity across multiple tumour types and in various settings. Despite having been approved on the basis of efficacy, the therapeutic index varies substantially in different settings for many of these agents. A major limitation is the current inability to personalise treatment a priori according to findings on measurement of a predictive biomarker. The roles of germline...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Angiogenesis Inhibitors
• Share to Antibodies, Monoclonal, Humanized
• Share to Bevacizumab